Novartis (NVS) is close to reaching a deal to acquire Cytokinetics (CYTK), Dana Cimilluca, Lauren Thomas and Laura Cooper of Wall Street Journal report, citing people familiar with the situation. The deal could be finalized as soon as this week, the paper notes. Cytokinetics has been running a sale process and it’s possible another suitor could reemerge, it adds. The Journal could not learn the potential price and other deal terms. Shares of Cytokinetics are up 10% to $102.70 following the report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CYTK:
- Liquidia added to Conviction Buy, named 2024 Top Pick at Needham
- Cytokinetics downgraded to Equal Weight from Overweight at Morgan Stanley
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Cytokinetics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- The biotech stocks to own in 2024, according to Piper Sandler
